Given that STK24 facilitates tumor immune evasion through its kinase activity, the prospect of employing small molecules specifically designed to target STK24 enzyme activity is a plausible strategy for combination therapy with an immune‐checkpoint blockade. The gene discussed is STK24; the disease is neoplasm.